

PRODUCT INFORMATION




VX-661

Item No. 21480

CAS Registry No.: 1152311-62-0
Formal Name: 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(2-hydroxy-1,1-dimethylethyl)-1H-indol-5-yl]-cyclopropanecarboxamide

Synonym: Tezacaftor
MF: C₂₆H₂₇F₃N₂O₆
FW: 520.5
Purity: ≥98%
UV/Vis.: λ_{max}: 233, 299 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

VX-661 is supplied as a crystalline solid. A stock solution may be made by dissolving the VX-661 in the solvent of choice, which should be purged with an inert gas. VX-661 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of VX-661 in ethanol is approximately 25 mg/ml and approximately 30 mg/ml in DMSO and DMF.

VX-661 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, VX-661 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. VX-661 has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

VX-661 is an investigational compound that promotes the maturation of delta F508 mutants of the cystic fibrosis transmembrane conductance regulator (CFTR).¹ Delta F508 CFTR represents a class of CFTR mutation that is characterized by impaired processing of misfolded CFTR proteins and reduced accumulation of the protein at the cell surface.¹ VX-661 is intended to facilitate trafficking of CFTR to the epithelial cell membrane. It may be combined with the CFTR potentiator ivacaftor (Item No. 15145) to stimulate both CFTR accumulation and opening at the apical epithelial surface.^{1,2}

References

1. Petit, R.S. and Fellner, C. CFTR modulators for the treatment of cystic fibrosis. *P.T.* **39(7)**, 500-511 (2014).
2. Veit, G., Avramescu, R.G., Perdomo, D., *et al.* Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression. *Sci. Transl. Med.* **6(246)**, 246RA97 (2014).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/06/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM